Global Diabetic Nephropathy Market 2014-2018

Global Diabetic Nephropathy Market 2014-2018

Category : Pharmaceuticals
Published On : March  2014
Pages : 64

------------ Or -------------

About Diabetic Nephropathy
Diabetic nephropathy is a disease of the kidney glomerulus, which is caused by high blood sugar.  When diabetes damages kidneys, which contain millions of tiny blood vessel clusters (glomeruli) that filter waste from the blood, this results in diabetic nephropathy, which is also known as diabetic kidney disease. Severe damage can lead to kidney failure or irreversible ESRD, requiring dialysis or a kidney transplant. Hypertension, or high blood pressure, is a complication of diabetes that is believed to contribute most directly to diabetic nephropathy. Treatment to limit progression of diabetic nephropathy involves glycemic control and blood pressure control.
TechNavio's analysts forecast the Global Diabetic Nephropathy market will grow at a CAGR of 5.19 percent over the period 2013-2018.
Covered in this Report
This report covers the present scenario and the growth prospects of the Global Diabetic Nephropathy market for the period 2014-2018. To calculate the market size, the report considers the revenue generated from the sales of various diabetic nephropathy drugs available in the market.
TechNavio's report, the Global Diabetic Nephropathy Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas and the EMEA and APAC regions; it also covers the Global Diabetic Nephropathy market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.
Key Regions
• Americas 
• EMEA        
Key Vendors
• Merck & Co. Inc.
• Mitsubishi Tanabe Pharma Corp.
• Novartis AG 
• Sanofi S.A.
Other Prominent Vendors
• AbbVie Inc.
• Ampio Pharmaceuticals Inc.
• Astellas Pharma Inc.
• Bayer AG 
• ChemoCentryx Inc.
• Eli Lilly and Co.
• GenKyoTex S.A.
• Glycadia Pharmaceuticals Inc.
• IMMD Inc.
• Mesoblast Ltd.
• NephroGenex Inc.
• Novo Nordisk A/S 
• NOXXON Pharma AG 
• OncoImmune Inc.
• Pfizer Inc.
• PhytoHealth Corp.
• Questcor Pharmaceuticals Inc.
• Reata Pharmaceuticals Inc. 
Key Market Driver
• Increase in Prevalence of Diabetes.
• For a full, detailed list, view our report.
Key Market Challenge
• Increasing Number of Patent Expirations.
• For a full, detailed list, view our report.
Key Market Trend
• Increase in Awareness of Diabetic Nephropathy Drugs.
• For a full, detailed list, view our report.
Key Questions Answered in this Report
• What will the market size be in 2018 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?
You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.
More Information about Diabetic Nephropathy

01. Executive Summary

02. List of Abbreviations

03. Scope of the Report

03.1 Market Overview

03.2 Product Offerings

Product Profiles

04. Market Research Methodology

04.1 Market Research Process

04.2 Research Methodology

05. Introduction

06. Market Landscape

06.1 Market Overview

06.2 Market Size and Forecast

06.3 DN Market in the US

06.3.1 Market Size and Forecast

06.4 DN Market in Europe

06.4.1 Market Size and Forecast

06.5 Five Forces Analysis

07. Pipeline Snapshot

08. Rate of Incidence and Prevalence

09. Geographical Segmentation

09.1 DN Market in the Americas

09.1.1 Market Size and Forecast

09.2 DN Market in the EMEA Region

09.2.1 Market Size and Forecast

09.3 DN Market in the APAC Region

09.3.1 Market Size and Forecast

10. Buying Criteria

11. Market Growth Drivers

12. Drivers and their Impact

13. Market Challenges

14. Impact of Drivers and Challenges

15. Market Trends

16. Trends and their Impact

17. Vendor Landscape

17.1 Competitive Scenario

17.1.1 Key News

17.1.2 Mergers and Acquisitions

17.2 Market Share Analysis 2013

17.3 Other Prominent Vendors

18. Key Vendor Analysis

18.1 Merck & Co. Inc.

18.1.1 Business Overview

18.1.2 Business Segmentation

18.1.3 Key Information

18.1.4 SWOT Analysis

18.2 Mitsubishi Tanabe Pharma Corp.

18.2.1 Business Overview

18.2.2 Key Information

18.2.3 SWOT Analysis

18.3 Novartis AG

18.3.1 Business Overview

18.3.2 Business Segmentation

18.3.3 Key Information

18.3.4 SWOT Analysis

18.4 Sanofi S.A.

18.4.1 Business Overview

18.4.2 Business Segmentation

18.4.3 Key Information

18.4.4 SWOT Analysis

19. Other Reports in this Series

List of Exhibits

Exhibit 1: Market Research Methodology

Exhibit 2: Global DN Market 2013-2018 (US$ billion)

Exhibit 3: DN Market in the US 2013-2018 (US$ billion)

Exhibit 4: DN Market in Europe 2013-2018 (US$ billion)

Exhibit 5: Global DN Market by Geographical Segmentation 2013

Exhibit 6: DN Market in the Americas 2013-2018 (US$ billion)

Exhibit 7: DN Market in the EMEA Region 2013-2018 (US$ billion)

Exhibit 8: DN Market in the APAC Region (US$ billion)

Exhibit 9: Global DN Market by Geographical Segmentation

Exhibit 10: Business Segmentation of Merck & Co. Inc.

Exhibit 11: Business Segmentation of Novartis AG

Exhibit 12: Business Segmentation of Sanofi S.A.

Enquiry Before Buy